ArticleThe American journal of surgical pathology2026
A Critical Examination of the Changes Proposed by the AJCCCCEP for the AJCC 9th Edition Colorectal Cancer Staging System.
Article in The American journal of surgical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The AJCC 8th edition colorectal cancer (CRC) staging system demonstrates non-hierarchical survival outcomes, with stage IIIA survivals consistently approximating stage I and exceeding stage II. The AJCC Colon Cancer Expert Panel (AJCCCCEP) has attempted to address this with its new proposal for the 9th edition, which incorporates tumor deposits (TDs) as an independent parameter and rebalances the relative significances of the T-stages and N-stages. We sought to critically assess these proposals in a large single-centre cohort. Patients undergoing CRC resection at our institution from 2005 to 2024 were staged according to the proposed system. Overall survival (OS) was evaluated using Kaplan-Meier analysis and pairwise comparisons made through log-rank tests ( P < 0.05). Four thousand two hundred fifty-seven CRC patients were identified (median age 74 y, 51% female; 36% node-positive, 17.5% TD positive). Median duration of follow-up was 8.5 years. The proposed staging produced hierarchical OS separation, and all pairwise comparisons achieved statistical significance except stage I versus IIA ( P =0.5), I versus IIB ( P =0.081), and IIA versus IIB ( P =0.10). Surprisingly, in subgroup analysis, patients with low T-stage (T1/T2) with lymph node metastases or tumor deposits (who comprised a small component of the proposed stage IIB grouping) demonstrated superior survival compared with T1/T2 node and tumor deposit-negative patients ( P =0.014). We conclude that the changes proposed by the AJCCCCEP for the 9th edition are an improvement and achieve hierarchical survival stratification. However, if our findings are confirmed in other independent cohorts, the proposal's application in T1/T2 stage disease may need refinement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.